Equities analysts predict that Kamada Ltd. (NASDAQ:KMDA) will post sales of $32.90 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Kamada’s earnings. The highest sales estimate is $35.30 million and the lowest is $30.50 million. Kamada posted sales of $19.07 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 72.5%. The firm is expected to issue its next earnings report on Tuesday, August 1st.

According to Zacks, analysts expect that Kamada will report full-year sales of $32.90 million for the current financial year, with estimates ranging from $100.00 million to $100.20 million. For the next year, analysts forecast that the firm will report sales of $135.31 million per share, with estimates ranging from $132.51 million to $138.10 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for Kamada.

Kamada (NASDAQ:KMDA) last posted its quarterly earnings data on Tuesday, May 16th. The biotechnology company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.03) by $0.08. The firm had revenue of $11.65 million for the quarter, compared to analysts’ expectations of $20.82 million. Kamada had a negative return on equity of 12.55% and a negative net margin of 11.31%.

A number of brokerages recently issued reports on KMDA. Jefferies Group LLC reissued a “buy” rating and set a $9.00 price objective on shares of Kamada in a research report on Wednesday, May 17th. Zacks Investment Research cut Kamada from a “hold” rating to a “strong sell” rating in a report on Thursday, May 18th.

Institutional investors have recently made changes to their positions in the stock. Edmond DE Rothschild Holding S.A. boosted its position in shares of Kamada by 17.8% in the first quarter. Edmond DE Rothschild Holding S.A. now owns 38,200 shares of the biotechnology company’s stock valued at $266,000 after buying an additional 5,772 shares during the last quarter. Norges Bank bought a new position in shares of Kamada during the fourth quarter valued at about $377,000. Acadian Asset Management LLC bought a new position in shares of Kamada during the first quarter valued at about $575,000. Finally, Renaissance Technologies LLC boosted its position in shares of Kamada by 20.4% in the fourth quarter. Renaissance Technologies LLC now owns 227,000 shares of the biotechnology company’s stock valued at $1,237,000 after buying an additional 38,500 shares during the last quarter. Institutional investors and hedge funds own 5.86% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was originally published by American Banking News and is owned by of American Banking News. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/07/06/32-90-million-in-sales-expected-for-kamada-ltd-nasdaqkmda-this-quarter.html.

Kamada (NASDAQ KMDA) traded down 1.67% on Thursday, reaching $5.90. 11,066 shares of the company’s stock traded hands. The firm has a 50-day moving average price of $7.16 and a 200-day moving average price of $6.74. The stock’s market capitalization is $213.31 million. Kamada has a 52 week low of $3.63 and a 52 week high of $8.61.

Kamada Company Profile

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.

Get a free copy of the Zacks research report on Kamada (KMDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.